Volume 21, Number 6—June 2015
Research
Oral Cholera Vaccine Coverage, Barriers to Vaccination, and Adverse Events following Vaccination, Haiti, 20131
Rania A. Tohme
, Jeannot François, Kathleen Wannemuehler, Preetha Iyengar, Amber Dismer, Paul Adrien, Terri B. Hyde, Barbara J. Marston, Kashmira A. Date, Eric D. Mintz, and Mark A. Katz
, Jeannot François, Kathleen Wannemuehler, Preetha Iyengar, Amber Dismer, Paul Adrien, Terri B. Hyde, Barbara J. Marston, Kashmira A. Date, Eric D. Mintz, and Mark A. Katz
Table 1
General characteristics of participants in oral cholera vaccine coverage survey, Haiti, 2013
| Characteristic | Area |
|
|---|---|---|
| Petite Anse, n = 1,121 | Cerca Carvajal, n = 809 | |
| Sex, no. (%) | ||
| M | 499 (43.1) | 407 (50.6) |
| F | 622 (56.9) | 402 (49.4) |
| Age, y, no. (%) | ||
| 1–4 | 206 (10.3) | 192 (13.8) |
| 5–14 | 353 (24.8) | 263 (35.0) |
| >15 | 562 (64.9) | 354 (51.1) |
| History of cholera, % (95% CI) | 38 3.5 (2.4–5.2) | 48 6.6 (4.5–9.6) |
1Results from this study were partially presented at the 49th US–Japan Conference on Cholera and Other Enteric Bacterial Infections; 2015 Jan 14–16; Gainesville, Florida, USA.
Page created: May 15, 2015
Page updated: May 15, 2015
Page reviewed: May 15, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.